Veracyte Inc   (VCYT)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $22.3300 $-0.58 -2.532%
Day's High: $23.41 Week Perf: -0.62 %
Day's Low: $ 22.17 30 Day Perf: -15.64 %
Volume (M): 728 52 Wk High: $ 32.40
Volume (M$): $ 16,245 52 Wk Avg: $24.37
Open: $23.30 52 Wk Low: $14.92

 Market Capitalization (Millions $) 1,618
 Shares Outstanding (Millions) 72
 Employees 677
 Revenues (TTM) (Millions $) 329
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) 76
 Capital Exp. (TTM) (Millions $) 8

Veracyte Inc
Veracyte Inc. is a leading genomic diagnostics company that provides solutions to patients who suffer from thyroid and lung diseases, as well as other types of cancer. The company is headquartered in South San Francisco, California, and has additional offices in Austin, Texas, and Italy.

Veracyte is focused on developing and commercializing genomic tests that enable doctors to diagnose and monitor patients with complex diseases more accurately. The company's products are based on RNA sequencing technology and genomic analysis, which help provide more precise information about the underlying genetic causes of disease.

Veracyte's flagship product, the Afirma Thyroid FNA Analysis, is used to diagnose thyroid nodules, which are a common medical problem that often requires further investigation to determine if they are benign or malignant. The Afirma Thyroid FNA Analysis delivers a diagnostic yield of up to 95%, allowing for more accurate diagnoses and reducing the number of unnecessary surgeries.

In addition to its thyroid diagnostic product, Veracyte also offers a lung cancer diagnostic test called the Percepta Bronchial Genomic Classifier. This test is used to diagnose early-stage lung cancer in patients who have received inconclusive biopsy results. It uses genomic analysis to identify the presence of cancer cells in the lungs, enabling doctors to start treatment at an earlier stage.

Veracyte's genomic testing products have won multiple awards and have been validated by leading medical institutions, such as the MD Anderson Cancer Center and the National Cancer Institute. The company has also secured partnerships with large pharmaceutical companies, such as Roche, to develop diagnostic tests for a wide range of diseases.

Along with its focus on developing genomic tests, Veracyte is also committed to advancing the field of genomic medicine through research and collaborations with academic institutions. The company has published numerous scientific papers and presented findings at major industry conferences.

Veracyte has a strong financial position, with significant revenues and ongoing growth. The company's market cap surpasses $3 billion, and its stock enjoys a consistently solid investor following. Its leadership team comprises experienced executives and key opinion leaders appointed from top-tier organizations to ensure consistent quality results and steady progress.

overall, Veracyte is seen an innovative, reliable, and valuable partner for patients and practitioners seeking more accurate diagnostic tools based on genomic technology.

   Company Address: 6000 Shoreline Court South San Francisco 94080 CA
   Company Phone Number: 243-6300   Stock Exchange / Ticker: NASDAQ VCYT
   VCYT is expected to report next financial results on November 02, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aclarion Inc

Aclarion Inc's Performance in Q2 2023 Raises Concerns Despite Impressive Revenue Growth

In this bearish article, we will examine Aclarion Inc's financial performance, primarily focusing on the financial time-frame closing on June 30, 2023, and its implications for the company's future. Despite an impressive revenue growth of 59.91%, there are underlying concerns that cannot be ignored. Additionally, recent trading activity and the stock's year-to-date performance indicate a declining trend. This article aims to highlight and explain these issues.
Financial Results and Revenue Growth:
Aclarion Inc showcased balanced books of $0.00 per share for the financial time-frame closing June 30, 2023. While this might initially seem positive from a profitability standpoint, it is vital to note that it remains unchanged both from the previous year and the prior reporting season. This stagnant performance raises concerns about Aclarion's ability to generate consistent profits.

Delwinds Insurance Acquisition Corp

Delwinds Insurance Acquisition Corp Reports Revenue of $0.012 Million in Q2 2023

Medical Laboratories Company Reports Modest Revenue in Q2 2023 Earnings Season
In the latest quarterly financial report released by the Medical Laboratories company, it has been revealed that the company generated revenue amounting to $0.012 million during the second quarter of the 2023 earnings season. While this figure may seem modest, it reflects the company's ongoing efforts to navigate the challenging market conditions currently impacting the healthcare industry.
Despite the relatively low revenue, Medical Laboratories remains focused on its core competencies and continues to deliver quality services to its clients. The company's strong reputation in the market has allowed it to maintain a steady stream of business, despite the headwinds it faces.

Invitae Corporation

Battling Strong Headwinds, Invitae Corporation Powers Through to Deliver Stellar Q2 2023 Earnings

Invitae Corporation, a prominent player in the Medical Laboratories sector, reported disappointing financial results for the April to June 30 2023 time-frame. The company's earnings per share (EPS) declined to $-0.78, compared to $-10.87 a year earlier, representing a significant increase in losses. Furthermore, revenue plummeted by 11.777% to $120.53 million from $136.62 million in the prior year, while sequentially increasing by a meager 2.706% from $117.36 million.
Revenue Contrast
Contrasting with the growth observed in the remainder of the Medical Laboratories sector, which recorded a revenue increase of 3.98% in the second quarter of 2023 compared to the same reporting period a year ago, Invitae Corporation suffered a substantial decrease in revenue. This decline puts the company at a clear disadvantage within its industry, indicating a failure to adapt to current market trends and potential internal inefficiencies.

Bionexus Gene Lab Corp

Bionexus Gene Lab Corp Reports Modest Growth in Top-line Revenue during Fiscal Q2 2023

Bionexus Gene Lab Corp (BGLC) recently released its financial results for the second quarter of 2023. In order to understand the implications of these results and their potential effects on the company's future, it is crucial to delve deeper into the figures and analyze them in the context of the overall medical laboratories sector.
Revenue Growth and Comparison:
During the second quarter of 2023, BGLC's revenue witnessed a slight increase of 3.289% to reach $2.57 million. This should be seen in relation to the corresponding period a year earlier, when the company generated $2.49 million in revenue. Furthermore, Q2 2023 revenue also recorded a sequential growth of 7.978% from $2.38 million.

Biocept Inc

Biocept Inc's Second Quarter 2023 Report Reveals Shocking -94.449% Drop in Revenue: a Critical Concern for the Medical Laboratories Sector

Biocept Inc (BIOC) has recently released its second-quarter financial report for 2023, and the results are disastrous. The company's revenue plummeted by a staggering -94.449% to a mere $0.59 million. This significant decline in revenue is alarming, especially when compared to the rest of the Medical Laboratories sector, which experienced revenue growth during the same period.
Furthermore, the company's shortfall per share has widened to $-3.50, a considerable deterioration from the previous year's reporting season. In comparison to the prior reporting season, revenue deteriorated sequentially by -12.481% from $0.67 million.


Veracyte Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com